<?xml version="1.0" encoding="UTF-8"?>
<p>The global research response to COVID‚Äê19 has been substantially larger than that observed with previous epidemics and pandemics. The potential drivers of this include the absence of proven therapies,
 <xref rid="mja250790-bib-0003" ref-type="ref">3</xref> ease of transmissibility,
 <xref rid="mja250790-bib-0004" ref-type="ref">4</xref> rapidity of global spread, and high hospitalisation and mortality rate
 <xref rid="mja250790-bib-0005" ref-type="ref">5</xref> coupled with greater pandemic preparedness and ease of greater global collaboration. It is concerning that only a minority of trials adhered to established markers of internal validity, such as blinding, allocation concealment, placebo where applicable, and a data safety monitoring committee presence.
</p>
